Joel Stettler on Procedures for Fall-Risk Patients

Patients who received pomalidomide, bortezomib, and dexamethasone achieved a median overall survival of 35.6 months compared with 31.6 months among patients treated with bortezomib and dexamethasone.

Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.

Findings from the PACIFIC-R trial showed that patients with EGFR-mutated non-small cell lung cancer experienced shorter progression-free survival with durvalumab than patients with EGFR-wildtype disease.

Seth Eisenberg, ASN, RN, OCN, BMTCN, emphasizes the importance of reducing nurse exposure to hazardous drugs—and ongoing research efforts to improve nursing safety.

The confirmed objective response rate with repotrectinib was 79% among tyrosine kinase inhibitor (TKI)-naïve patients and 38% among TKI-pretreated patients.

The median progression-free survival was 25.5 months with osimertinib plus chemotherapy and 16.7 months with osimertinib alone.